Open Access2-deoxy-2-(18F)fluoro-D-glucose positron emission tomography/computed tomography imaging in paediatric oncology
Author(s) -
John Freebody,
Eva A Wegner,
Monica A. Rossleigh
Publication year - 2014
Publication title -
world journal of radiology
Language(s) - Uncategorized
Resource type - Journals
ISSN - 1949-8470
DOI - 10.4329/wjr.v6.i10.741
Subject(s) - medicine , positron emission tomography , radiology , pediatric oncology , hodgkin lymphoma , lymphoma , pet ct , nuclear medicine , medical physics , cancer
Positron emission tomography (PET) is a minimally invasive technique which has been well validated for the diagnosis, staging, monitoring of response to therapy, and disease surveillance of adult oncology patients. Traditionally the value of PET and PET/computed tomography (CT) hybrid imaging has been less clearly defined for paediatric oncology. However recent evidence has emerged regarding the diagnostic utility of these modalities, and they are becoming increasingly important tools in the evaluation and monitoring of children with known or suspected malignant disease. Important indications for 2-deoxy-2-((18)F)fluoro-D-glucose (FDG) PET in paediatric oncology include lymphoma, brain tumours, sarcoma, neuroblastoma, Langerhans cell histiocytosis, urogenital tumours and neurofibromatosis type I. This article aims to review current evidence for the use of FDG PET and PET/CT in these indications. Attention will also be given to technical and logistical issues, the description of common imaging pitfalls, and dosimetric concerns as they relate to paediatric oncology.